- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04482296
Effect of Zinc Supplementation on Depression in SSRI-treated Major Depressive Disorder Patients
Effect of Zinc Supplementation on Depression in Selective Serotonin Reuptake Inhibitors-treated Major Depressive Disorder Patients
Title:
Effect of zinc supplementation on depression in SSRIs-treated MDD patients.
Purpose: Depression is the single largest contributor to global disability as has been ranked by WHO (2015), in humans including both male and female.Studies have suggested that conventional presently available anti-depressive medicines are effective for one third to one-half (19-34%) of the patients suffering from depression, leaving the rest of patients to suffer from recurrence or incomplete cure. Researchers throughout the world are involved to obtain new pharmacotherapy for the treatment of MDD. Zinc is an important micronutrient of the human body which is implicated as an essential component in various systemic wellbeing including the central nervous system.
Methods: The study would be randomized, double-blind, placebo-controlled prospective interventional trial and it would be conducted in the Department of Pharmacology and in collaboration with the Department of Psychiatry, BSMMU, from date of approval by the IRB to August 2020. A total of 100 patients suffering from mild to moderate major depression will be selected following to inclusion and exclusion criteria and serum Zinc levels will be assessed. The diagnosis of patients suffering from MDD and the selection of drugs and dosage would be performed by a senior professor of the Psychiatry department. After completing the necessary formalities including the informed consent of the patients, the patient would undergo a selected questionnaire (DASS-21) to assess his/her degree of severity of the disease. The patients would be randomly allocated into two groups: group A (control group) and B (intervention group). Group A would consist of 50 patients who will receive a placebo with SSRIs for 8 weeks. Group B would consist of 50 patients who will receive SSRIs plus Zinc sulfate (30mg/day) orally for 8 weeks, after which at follow up, the severity of depression will be assessed. The blood sample will be collected to measure serum zinc level at baseline and again after 8 weeks of therapeutic intervention.
Ethical consideration
The study will follow the principles of the Declaration of Helsinki and of the World Medical Assembly. Patients will be informed about the study in easy language and then informed consent will be taken. The study has no potential risk to the patients. Confidentiality will be strictly maintained.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Dhaka, Bangladesh
- BSMMU
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Newly diagnosed patients with major depressive disorder diagnosed from the Psychiatry department of BSMMU according to the diagnostic protocol which fulfills DSM-4 criteria and SCID 1 Bangla version.
- Patients treated with only SSRIs.
- Mild to moderate MDD patients.
- Age: 18-55 years.
- Sex: Both male and female.
Exclusion criteria:
- Age < 18 years and > 55 years.
- Patients receiving other antidepressants and dietary supplements in the last two months.
- Patients with other psychiatric disorders (such as anxiety disorder, schizophrenia, bipolar disorder, alcoholism).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: SSRI with placebo
50 patients who will receive placebo with SSRIs for 8 weeks
|
|
Active Comparator: SSRI with zinc sulfate
50 patients who will receive SSRIs with zinc sulfate for 8 weeks
|
Zinc sulfate (30 mg) once daily for 8 weeks SSRI
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To measure the serum zinc level in SSRI-treated MDD patients pre and post supplementation of zinc.
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Satabdi Ghosh, MBBS, BSMMU(Recruiting), Dhaka, Bangladesh, 1000
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BSMMU/2019/8875
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MDD
-
Autobahn Therapeutics, Inc.Novotech (Australia) Pty LimitedCompleted
-
University of California, San FranciscoCompleted
-
AstraZenecaCompleted
-
Unity Health TorontoActive, not recruiting
-
University of California, San FranciscoCompleted
-
University of Texas at AustinWithdrawn
-
Research Foundation for Mental Hygiene, Inc.Terminated
-
H. Lundbeck A/SCompletedAnxiety Disorders | MDDEstonia, France, Italy, Korea, Republic of, Poland, Spain
-
Duke UniversityCompleted
Clinical Trials on SSRI with Zinc Sulfate
-
Cairo UniversityUnknown
-
International Centre for Diarrhoeal Disease Research...Completed
-
Instituto Nacional de Salud Publica, MexicoUNICEFCompletedDiarrhea, Infantile | Diarrhoea;AcuteMexico
-
Hormozgan University of Medical SciencesCompleted
-
University of VermontNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting
-
Babylon UniversityMinistry of Health, IraqCompletedAsthenozoospermiaIraq
-
mahmoud hussein hadwanMinistry of Health, IraqCompleted
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedGastric Carcinoma | Unresectable Pancreatic Carcinoma | Liver and Intrahepatic Bile Duct Carcinoma | Unresectable Esophageal CarcinomaUnited States
-
Universidad Nacional Autonoma de MexicoHospital General de Mexico; Hospital Pediatrico de CoyoacanCompletedPneumonia | Children, OnlyMexico
-
Mansoura UniversityCompleted